Sage Therapeutics, Inc. (SAGE)

12,89 -0,44 (-3,30 %) À la clôture : 04:00PM EDT

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 487

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Barry E. Greene	President, CEO & Director	1,29M	S.O.	1963
Ms. Kimi E. Iguchi CPA	CFO & Treasurer	665,37k	144,99k	1962
Ms. Anne Marie Cook Esq.	Senior VP, General Counsel & Secretary	711,6k	S.O.	1962
Mr. Christopher Benecchi	Chief Business Officer	703,76k	S.O.	1972
Dr. Laura Gault M.D., Ph.D.	Chief Medical Officer	334,08k	S.O.	S.O.
Mr. Matt Lasmanis	Chief Technology & Innovation Officer	S.O.	S.O.	S.O.
Mr. Mike Quirk	Chief Scientific Officer	S.O.	S.O.	S.O.
Ashley Kaplowitz	Director of Investor Relations	S.O.	S.O.	S.O.
Ms. Erin E. Lanciani	Chief People & Experience Officer	S.O.	S.O.	1969
Dr. Amy Schacterle Ph.D.	Senior Vice President of R&D Strategy and Business Management	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sage Therapeutics, Inc. en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 7; Société : 7; Droits des actionnaires : 8; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.